Synthon and MIVAC Development enter into exclusive research collaboration and commercial licensing agreement in multiple sclerosis
Synthon and MIVAC Development announced that they have entered into a new, exclusive and broad ranging research and development collaboration to produce innovative treatments for patients with multiple sclerosis.
The collaboration will combine Synthon’s expertise in the pharmaceutical arena and business acumen with MIVAC Development’s tolerance-inducing fusion protein technology.
Under the collaboration, Synthon and MIVAC Development will create multiple new therapeutic candidates, research and screen these to identify novel lead compounds which Synthon will develop further into the clinic and bring onto the market.
The result of this collaboration could be a new treatment paradigm for multiple sclerosis patients offering superior efficacy with greater ease of use and improved tolerability.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.